Literature DB >> 15984424

Biopolymer-based delivery systems for advanced imaging and skeletal tissue-specific therapeutics.

Scott C Miller1, Dong Wang, Pavla Kopecková, Jindrich Kopecek.   

Abstract

There is considerable advantage in developing tissue-specific delivery systems for therapeutic and diagnostic applications. Synthetic water-soluble polymeric delivery systems have been developed to allow selective delivery of therapeutic and imaging agents to musculoskeletal tissues. For mineralized tissues, bone-targeting agents such as aspartic acid octapeptide could concentrate the polymer conjugates to bone surfaces including resorption sites, which was demonstrated with routine bone histomorphometry. For bone-associated soft tissues, other targeting approaches based on pathophysiological properties unique to the local tissue environment, such as the leaky vasculature in arthritic joints, were utilized to achieve the selective deposition of the polymeric delivery systems to the desired sites. For this study, magnetic resonance imaging (MRI) was used to assess real-time pharmacokinetics and biodistribution of the MRI contrast agent conjugated polymer in major organs including skeletal tissues. The MRI data were then correlated with other standard imaging methods such as pQCT and DXA as well as routine histopathology and skeletal histomorphometry. Clearly, biopolymeric delivery systems may be used to improve the pharmacological and pharmacokinetic properties of different therapeutic agents for musculoskeletal diseases such as osteoporosis and arthritis. In addition, this or related technologies may also be useful to improve diagnosis and medical imaging with positron emission tomography, gamma scintigraphy, or other technologies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15984424     DOI: 10.1007/BF03026333

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  20 in total

1.  Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo.

Authors:  K R Kozak; B C Crews; J L Ray; H H Tai; J D Morrow; L J Marnett
Journal:  J Biol Chem       Date:  2001-07-10       Impact factor: 5.157

2.  Permeability of human synovial membrane to plasma proteins. Relationship to molecular size and inflammation.

Authors:  I Kushner; J A Somerville
Journal:  Arthritis Rheum       Date:  1971 Sep-Oct

3.  Effect of the chemical structure of N-(2-hydroxypropyl)methacrylamide copolymers on their ability to induce antibody formation in inbred strains of mice.

Authors:  B Rihová; J Kopecek; K Ulbrich; M Pospisil; P Mancal
Journal:  Biomaterials       Date:  1984-05       Impact factor: 12.479

Review 4.  HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action.

Authors:  J Kopecek; P Kopecková; T Minko; Z Lu
Journal:  Eur J Pharm Biopharm       Date:  2000-07       Impact factor: 5.571

5.  The arthrotropism of macromolecules in adjuvant-induced arthritis rat model: a preliminary study.

Authors:  Dong Wang; Scott C Miller; Monika Sima; Dennis Parker; Henry Buswell; K Craig Goodrich; Pavla Kopecková; Jindrich Kopecek
Journal:  Pharm Res       Date:  2004-10       Impact factor: 4.200

6.  Animal models of rheumatoid arthritis.

Authors:  A Bendele
Journal:  J Musculoskelet Neuronal Interact       Date:  2001-06       Impact factor: 2.041

7.  Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems.

Authors:  Dong Wang; Scott Miller; Monika Sima; Pavla Kopecková; Jindrich Kopecek
Journal:  Bioconjug Chem       Date:  2003 Sep-Oct       Impact factor: 4.774

8.  Selective inhibition of the collagenolytic activity of human cathepsin K by altering its S2 subsite specificity.

Authors:  Fabien Lecaille; Youngchool Choe; Wolfgang Brandt; Zhenqiang Li; Charles S Craik; Dieter Brömme
Journal:  Biochemistry       Date:  2002-07-02       Impact factor: 3.162

9.  Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.

Authors:  P A Vasey; S B Kaye; R Morrison; C Twelves; P Wilson; R Duncan; A H Thomson; L S Murray; T E Hilditch; T Murray; S Burtles; D Fraier; E Frigerio; J Cassidy
Journal:  Clin Cancer Res       Date:  1999-01       Impact factor: 12.531

10.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

Authors:  Y Matsumura; H Maeda
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

View more
  1 in total

1.  Feasibility of using a bone-targeted, macromolecular delivery system coupled with prostaglandin E(1) to promote bone formation in aged, estrogen-deficient rats.

Authors:  S C Miller; H Pan; D Wang; B M Bowman; P Kopecková; J Kopecek
Journal:  Pharm Res       Date:  2008-08-29       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.